โ† BridgeBio Pharma, Inc. BBIO

Latest FY: 2026 Healthcare Biotechnology
Market Price $75.39
Market Cap $14.77B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2026)
$502.08M
Full year reported
Net Income
-$724.93M
Net Margin: N/A
Free Cash Flow
-$1.72M
FCF Yield: -0.01%
EPS (Diluted) โ†‘99.7% YoY
$-0.01
Basic: $-0.01
Return on Equity Efficiency
-884.5%
ROA: -329,659.4%

๐Ÿ“Š Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

๐Ÿ“ˆ Year-over-Year (YoY) Growth History (BBIO)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2017 $0.0M โ€” $0.0M $-30.6M โ€” โ€” โ€” โ€” โ€” $-40.5M $-41.0M โ€”
FY 2018 $2.0M +5,038.5% $2.0M $-130.7M -327.8% โ€” โ€” โ€” โ€” $-136.6M $-138.8M -239.0%
FY 2019 $40.6M +1,924.0% $-171.9M $-260.6M -99.3% โ€” โ€” โ€” 0.00% $-253.6M $-256.2M -84.6%
FY 2020 $8.2M -79.7% $-473.6M $-448.7M -72.2% โ€” โ€” โ€” 0.00% $-399.7M $-407.2M -58.9%
FY 2021 $69.7M +745.1% $22.9M $-562.5M -25.4% โ€” โ€” โ€” 0.00% $-497.9M $-511.2M -25.5%
FY 2022 $77.6M +11.4% $74.2M $-481.2M +14.5% $-3.26 โ€” โ€” 0.00% $-419.5M $-424.3M +17.0%
FY 2023 $9.3M -88.0% $6.9M $-643.2M -33.7% $-3.95 -21.2% โ€” 0.00% $-527.7M $-529.0M -24.7%
FY 2024 $221.9M +2,285.3% $122.6M $-535.8M +16.7% $-2.88 +27.1% โ€” 0.00% $-520.7M $-521.7M +1.4%
FY 2025 $502.1M +126.3% $376.9M $-724.9M -35.3% $-3.78 -31.2% โ€” 0.00% $-445.9M $-447.0M +14.3%
FY 2026 โ€” โ€” โ€” โ€” โ€” $-0.01 +99.7% โ€” 0.00% $-0.6M โ€” โ€”
$

Valuation

Market Price $75.39
Market Cap $14.77B
Enterprise Value $14.77B
P/E Ratio N/A
P/B Ratio 180.16
FCF Yield -0.01%
Dividend Yield N/A
Shares Outstanding 195,861,200
%

Profitability & Margins

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
Return on Equity (ROE) -884.47%
Return on Assets (ROA) -329,659.44%
Asset Turnover 2,283.17x
Revenue 3-Yr CAGR N/A
๐Ÿ›ก๏ธ

Financial Health & Liquidity

Current Ratio 0.14
Cash Ratio 0.01
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $12.57K
Total Debt N/A
Book Value / Share $0.42
๐Ÿ’ง

Cash Flow Efficiency

Operating Cash Flow -$625.46K
Capital Expenditures (CapEx) $1.10M
Free Cash Flow -$1.72M
OCF / Revenue -0.12%
FCF / Revenue -0.34%
FCF 3-Yr CAGR N/A
๐Ÿท๏ธ

Per Share Metrics

EPS (Diluted) $-0.01
EPS (Basic) $-0.01
Dividends / Share N/A
Book Value / Share $0.42
EPS YoY Growth 99.74%
๐Ÿ›๏ธ

Balance Sheet (FY 2026)

Total Assets $219.90K
Total Liabilities -$81.74M
Stockholders' Equity $81.96M
Current Assets $204.48K
Current Liabilities $1.42M